{
    "id": 23873,
    "fullName": "SMO L221R",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SMO L221R lies within an extracellular domain of the Smo protein (UniProt.org). L221R (corresponding to L225R in mouse) has been demonstrated to confer Hedgehog pathway inhibitor resistance in mouse models (PMID: 20881279), but has not been biochemically characterized and therefore, its effect on Smo protein function is unknown (PubMed, Apr 2020).",
            "references": [
                {
                    "id": 14176,
                    "pubMedId": 20881279,
                    "title": "Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20881279"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6608,
        "geneSymbol": "SMO",
        "terms": [
            "SMO",
            "CRJS",
            "FZD11",
            "Gx",
            "SMOH"
        ]
    },
    "variant": "L221R",
    "createDate": "06/28/2016",
    "updateDate": "04/02/2020",
    "referenceTranscriptCoordinates": {
        "id": 123196,
        "transcript": "NM_005631",
        "gDna": "chr7:g.129205327T>G",
        "cDna": "c.662T>G",
        "protein": "p.L221R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8099,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing SMO L225R (corresponding to SMO L221R in human) were resistant to Odomzo (sonidegib) in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26150,
                "profileName": "PTCH1 inact mut SMO L221R"
            },
            "therapy": {
                "id": 1428,
                "therapyName": "Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8100,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing SMO L225R (corresponding to SMO L221R in human) were resistant to Erivedge (vismodegib) in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26150,
                "profileName": "PTCH1 inact mut SMO L221R"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8101,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, tumor cells derived from spontaneous medulloblastoma of heterozygous PTCH1 knockout mice over expressing SMO L225R (corresponding to SMO L221R in human) were resistant to LEQ506 in culture (PMID: 26130651).",
            "molecularProfile": {
                "id": 26150,
                "profileName": "PTCH1 inact mut SMO L221R"
            },
            "therapy": {
                "id": 2416,
                "therapyName": "LEQ506",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6547,
                    "pubMedId": 26130651,
                    "title": "RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24598,
            "profileName": "SMO L221R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26150,
            "profileName": "PTCH1 inact mut SMO L221R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123196,
            "transcript": "NM_005631",
            "gDna": "chr7:g.129205327T>G",
            "cDna": "c.662T>G",
            "protein": "p.L221R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}